Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells

The clinical success of EGFR inhibitors in patients with lung cancer is limited by the inevitable development of treatment resistance. Here, we show that inhibition of SREBP increase gefitinib sensitivity in vitro and in vivo. Interference of SREBP1 binding partner MARVELD1 potentiate the therapeuti...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Li, Jiajin, Yan, Hui, Zhao, Li, Jia, Wenzhi, Yang, Hao, Liu, Liu, Zhou, Xiang, Miao, Ping, Sun, Xiaoguang, Song, Shaoli, Zhao, Xiaoping, Liu, Jianjun, Huang, Gang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2016
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239560/
https://ncbi.nlm.nih.gov/pubmed/27447558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10721
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller